Medium materiality6/10
Avalyn Pharma price target raised to $57 from $53 at Morgan Stanley
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Morgan Stanley raises AVLN price target to $57 from $53, signaling a more favorable longer-term view. Current price at signal was $37.38.
- Target raised to $57 (from $53) by Morgan Stanley.
- Current price $37.38.
Key facts
- 01
Target: $57
- 02
Posted price: $37.38
- 03
Analyst firm: Morgan Stanley
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.